Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysis.

BMC Cardiovasc Disord · 2025 · PMC12275272 · PMID 40684113

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Results showed a marginally significant risk reduction for patients treated with SGLT2 inhibitors compared to placebo (RR: 0.67, 95% CI: 0.47–0.95).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.